ZA200806386B - Thiazole compounds as protein kinase B (PKB) Inhibitors - Google Patents

Thiazole compounds as protein kinase B (PKB) Inhibitors

Info

Publication number
ZA200806386B
ZA200806386B ZA200806386A ZA200806386A ZA200806386B ZA 200806386 B ZA200806386 B ZA 200806386B ZA 200806386 A ZA200806386 A ZA 200806386A ZA 200806386 A ZA200806386 A ZA 200806386A ZA 200806386 B ZA200806386 B ZA 200806386B
Authority
ZA
South Africa
Prior art keywords
pkb
inhibitors
protein kinase
thiazole compounds
thiazole
Prior art date
Application number
ZA200806386A
Other languages
English (en)
Inventor
Zeng Qingping
John G Allen
Matthew P Bourbeau
Dominguez Celia
Christopher H Fotsch
Hah Nianhe
Hong Fang-Tsao
Huang Xin
Matthew R Lee
Li Aiwen
Liu Qingyian
James T Rider
Tadesse Seifu
Andrew S Tasker
Vellarkad N Viswanadhan
Wang Xianghong
Kurt E Weiler
George E Wohlhieter
Yao Guomin
Yuan Chester Chenguang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ZA200806386B publication Critical patent/ZA200806386B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
ZA200806386A 2006-01-18 2008-07-23 Thiazole compounds as protein kinase B (PKB) Inhibitors ZA200806386B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75954606P 2006-01-18 2006-01-18

Publications (1)

Publication Number Publication Date
ZA200806386B true ZA200806386B (en) 2009-11-25

Family

ID=38180602

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200806386A ZA200806386B (en) 2006-01-18 2008-07-23 Thiazole compounds as protein kinase B (PKB) Inhibitors

Country Status (21)

Country Link
US (2) US7514566B2 (US08084479-20111227-C00086.png)
EP (1) EP1981884B1 (US08084479-20111227-C00086.png)
JP (1) JP5199885B2 (US08084479-20111227-C00086.png)
KR (1) KR20080091369A (US08084479-20111227-C00086.png)
CN (1) CN101421265A (US08084479-20111227-C00086.png)
AR (1) AR059064A1 (US08084479-20111227-C00086.png)
AU (1) AU2007207743B2 (US08084479-20111227-C00086.png)
BR (1) BRPI0706621A2 (US08084479-20111227-C00086.png)
CA (1) CA2636077C (US08084479-20111227-C00086.png)
CR (1) CR10211A (US08084479-20111227-C00086.png)
EA (1) EA200801716A1 (US08084479-20111227-C00086.png)
ES (1) ES2389062T3 (US08084479-20111227-C00086.png)
IL (1) IL192751A0 (US08084479-20111227-C00086.png)
MY (1) MY149143A (US08084479-20111227-C00086.png)
NO (1) NO20083572L (US08084479-20111227-C00086.png)
PE (1) PE20071114A1 (US08084479-20111227-C00086.png)
TW (1) TW200738657A (US08084479-20111227-C00086.png)
UA (1) UA91895C2 (US08084479-20111227-C00086.png)
UY (1) UY30098A1 (US08084479-20111227-C00086.png)
WO (1) WO2007084391A2 (US08084479-20111227-C00086.png)
ZA (1) ZA200806386B (US08084479-20111227-C00086.png)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2583217C (en) 2004-10-18 2011-05-31 Amgen Inc. 1,3,4-thiadiazole compounds as protein kinase inhibitors
MY149143A (en) 2006-01-18 2013-07-15 Amgen Inc Thiazole compounds as protien kinase b (pkb) inhibitors
JP2010518159A (ja) 2007-02-13 2010-05-27 シェーリング コーポレイション 機能選択性α2Cアドレナリン受容体アゴニスト
US7919504B2 (en) * 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
JP2010533715A (ja) * 2007-07-17 2010-10-28 アムジエン・インコーポレーテツド 複素環系pkb調節剤
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
JP2011525929A (ja) * 2008-06-26 2011-09-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Akt活性の阻害剤
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
EP2326631A4 (en) * 2008-08-18 2012-03-21 Univ Yale MODULATORS OF MIF
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
LT2356109T (lt) * 2008-10-10 2017-03-27 Vm Discovery, Inc. Kompozicijos ir būdai, skirti alkoholio vartojimo sutrikimų, skausmo ir kitų ligų gydymui
WO2010080503A1 (en) * 2008-12-19 2010-07-15 Genentech, Inc. Heterocyclic compounds and methods of use
EP2387570A1 (en) * 2009-01-15 2011-11-23 Amgen, Inc Fluoroisoquinoline substituted thiazole compounds and methods of use
EP2440556A1 (en) * 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
NZ597107A (en) 2009-06-25 2013-12-20 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
ES2530436T3 (es) * 2009-10-08 2015-03-02 Glaxosmithkline Llc Combinación
WO2011044414A1 (en) * 2009-10-08 2011-04-14 Glaxosmithkline Llc Combination
CA2777561A1 (en) * 2009-10-12 2011-04-21 Glaxosmithkline Llc Combination
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
SG10201500895XA (en) 2009-11-05 2015-04-29 Rhizen Pharmaceuticals Sa Chromen-4-one Derivatives As Kinase Modulators
JP5747352B2 (ja) * 2010-03-15 2015-07-15 国立大学法人広島大学 チエノピリジン誘導体を用いた有機半導体デバイス
JP5578705B2 (ja) * 2010-03-29 2014-08-27 公益財団法人相模中央化学研究所 (アリール)ジフルオロ酢酸エステル誘導体及びその製造方法
CA2794859A1 (en) * 2010-04-16 2011-10-20 Abbvie Inc. Phthalazin-(2h)-one inhibitors of kinases
US20130102605A1 (en) * 2010-04-23 2013-04-25 Peng Liang Inhibitors of akt activity
WO2011130921A1 (en) * 2010-04-23 2011-10-27 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
CA2833935C (en) 2011-05-04 2020-09-15 Dhanapalan Nagarathnam Novel compounds as modulators of protein kinases
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
CN103304468A (zh) * 2012-03-13 2013-09-18 华东师范大学 一种氧化吲哚的一锅法串联合成方法
US9499533B2 (en) 2012-03-27 2016-11-22 Shionogi & Co., Ltd. Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity
WO2013173382A1 (en) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
PL2870157T3 (pl) 2012-07-04 2018-01-31 Rhizen Pharmaceuticals S A Selektywne inhibitory pi3k delta
US20160002185A1 (en) 2013-02-19 2016-01-07 Amgen Inc. Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
RU2015143526A (ru) * 2013-03-13 2017-04-19 Бостон Байомедикал, Инк. Производные 3-(арил или гетероарил)метилениндолин-2-она в качестве ингибиторов киназного пути раковых стволовых клеток для лечения рака
CA2906538C (en) 2013-03-14 2021-02-02 Ana Gonzalez Buenrostro Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
MX2020013670A (es) 2013-11-11 2022-09-30 Amgen Inc Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
MX371167B (es) * 2015-03-02 2020-01-21 Rigel Pharmaceuticals Inc Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
MX2018010894A (es) * 2016-03-10 2018-11-09 Astrazeneca Ab Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma.
TW201843139A (zh) 2017-03-30 2018-12-16 瑞士商赫孚孟拉羅股份公司 作為hpk1之抑制劑的異喹啉
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
NZ762856A (en) 2017-10-05 2020-07-31 Fulcrum Therapeutics Inc P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
AU2019262589B2 (en) 2018-05-04 2022-07-07 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
CR20210665A (es) 2019-05-21 2022-01-25 Amgen Inc Formas en estado sólido
CN114391012A (zh) * 2019-08-02 2022-04-22 美国安进公司 作为kif18a抑制剂的吡啶衍生物
WO2021076655A1 (en) 2019-10-15 2021-04-22 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021126816A1 (en) 2019-12-16 2021-06-24 Amgen Inc. Dosing regimen of a kras g12c inhibitor
CN111603466B (zh) * 2020-06-29 2022-07-22 江南大学 一种乙酮类化合物在制备治疗肿瘤药物中的应用
CN114014787B (zh) * 2022-01-10 2022-03-22 苏州开元民生科技股份有限公司 一种制备(2s,3r)-对甲砜基苯丝氨酸乙酯的不对称合成方法
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591600A (en) * 1969-07-07 1971-07-06 Stauffer Chemical Co 2-aminothiazole phosphates and phosphonates
GB1435139A (en) * 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
JPS5239827B2 (US08084479-20111227-C00086.png) 1973-11-08 1977-10-07
US4086239A (en) * 1977-07-01 1978-04-25 Stauffer Chemical Company Thiazole bis-phosphates and phosphonates, intermediates, and insecticidal compositions and methods
DK150068C (da) 1978-06-02 1987-06-29 Pfizer Analogifremgangsmaade til fremstilling af aminothiazoler
US4297365A (en) * 1978-08-04 1981-10-27 Ciba-Geigy Corporation Benzimidazoles and pharmaceutical preparations containing such compounds
US4451471A (en) * 1981-03-18 1984-05-29 Ciba-Geigy Corporation Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same
FR2511375A1 (fr) * 1981-08-17 1983-02-18 Rhone Poulenc Sante Nouveaux derives de la cephalosporine, leur preparation et les medicaments qui les contiennent
DE3630732A1 (de) * 1986-09-10 1988-03-17 Bayer Ag 2-cyano-2-alkoximino-acetamide
US5232921A (en) * 1987-03-12 1993-08-03 Sanofi Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions
JPH0753666B2 (ja) 1987-09-14 1995-06-07 久光製薬株式会社 置換ジフェニルチアゾール誘導体からなる抗炎症剤
FR2636628B1 (fr) * 1988-08-25 1990-12-28 Sanofi Sa Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant
US5302608A (en) * 1988-11-18 1994-04-12 Takeda Chemical Industries, Ltd. Age formation inhibitors
US5145860A (en) * 1989-01-05 1992-09-08 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds and pharmaceutical composition comprising the same
US5550138A (en) * 1992-03-25 1996-08-27 Takeda Chemical Industries, Ltd. Condensed thiadiazole derivative, method of its production, and use thereof
WO1996016650A1 (fr) * 1994-11-29 1996-06-06 Hisamitsu Pharmaceutical Co., Inc. Antibacterien et bactericide comprenant un derive de 2-aminothiazole et sels de ce derive
FR2735777B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US6407124B1 (en) * 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
CA2332325A1 (en) 1998-06-18 1999-12-23 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
EP1150565A1 (en) 1999-02-08 2001-11-07 LION bioscience AG Thiazole derivatives and combinatorial libraries thereof
AUPP873799A0 (en) * 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001114690A (ja) * 1999-08-06 2001-04-24 Takeda Chem Ind Ltd p38MAPキナーゼ阻害剤
CA2381215A1 (en) * 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. P38map kinase inhibitors
WO2001074811A2 (en) * 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
US6586453B2 (en) * 2000-04-03 2003-07-01 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
US7074934B2 (en) * 2000-06-13 2006-07-11 Tularik Limited Serine protease inhibitors
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
JP4689801B2 (ja) 2000-08-09 2011-05-25 ケミプロ化成株式会社 アミノチアゾール誘導体の製造方法
JP2002053566A (ja) 2000-08-11 2002-02-19 Japan Tobacco Inc チアゾール化合物及びその医薬用途
GB0114185D0 (en) * 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
AR032653A1 (es) * 2001-02-09 2003-11-19 Telik Inc Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
DE60208630T2 (de) * 2001-05-11 2006-08-17 Pfizer Products Inc., Groton Thiazolderivate und ihre Verwendung als cdk-Inhibitoren
EP1402900A1 (en) * 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Medicinal compositions
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
MXPA04002914A (es) * 2001-09-28 2005-06-20 Cyclacel Ltd N- (4- (4-metiltiazol-5-il)pirimidin-2-il) -n-fenilaminas como compuestos antiproliferativos.
GB0123589D0 (en) * 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
US20050004134A1 (en) * 2001-11-08 2005-01-06 Hideo Tsutsumi Thiazole derivative and pharmaceutical use thereof
CN1633293A (zh) 2002-02-13 2005-06-29 药物基因实验室有限公司 5-ht2b受体拮抗剂
TWI314928B (en) * 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
DE60316411T2 (de) * 2002-02-28 2008-06-12 F. Hoffmann-La Roche Ag Thiazolderivate als npy-rezeptorantagonisten
WO2004026226A2 (en) * 2002-05-10 2004-04-01 Cytokinetics, Inc. Compounds, compositions and methods
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
WO2004033439A1 (en) * 2002-10-09 2004-04-22 Pfizer Products Inc. Thiazole compounds for the treatment of neurodegenerative disorders
US20040122016A1 (en) 2002-10-30 2004-06-24 Jingrong Cao Compositions useful as inhibitors of rock and other protein kinases
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
FR2850380B1 (fr) * 2003-01-23 2006-07-07 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd 7員複素環誘導体
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
JP2007512230A (ja) * 2003-08-20 2007-05-17 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用な(4−アミノ−1,2,5−オキサジアゾール−4−イル)−ヘテロ芳香族化合物
ZA200602755B (en) * 2003-09-06 2007-06-27 Vertex Pharma Modulators of ATP-binding cassette transporters
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
GB0329275D0 (en) 2003-12-18 2004-01-21 Merck Sharp & Dohme Therapeutic treatment
AU2005205201B2 (en) 2004-01-12 2011-05-12 Merck Serono Sa Thiazole derivatives and use thereof
BRPI0506880A (pt) * 2004-01-16 2007-06-26 Sanofi Aventis derivados de acilaminotiazol, sua preparação e sua aplicação em terapêutica
EP1709018B1 (fr) * 2004-01-16 2011-07-20 Sanofi-Aventis Derives d'acylaminothiazole et leur application comme inhibiteurs de beta-amyloide
US20070185152A1 (en) * 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
AU2005225635B2 (en) 2004-03-23 2010-06-24 Pfizer Products Inc. Imidazole compounds for the treatment of neurodegenerative disorders
CN1989131A (zh) * 2004-03-30 2007-06-27 希龙公司 取代的噻吩衍生物用作抗癌药
CA2563374A1 (en) * 2004-04-27 2005-12-08 Research Development Foundation Antagonism of tgf-.beta.superfamily receptor signaling
WO2005113579A1 (en) * 2004-05-21 2005-12-01 Mpex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors and methods of treating bacterial infections
GB0411791D0 (en) 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
RU2007109073A (ru) 2004-08-13 2008-09-20 Дженентек, Инк. (Us) Ингибиторы для атф-зависимого фермента на основе тиазола
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
CA2583217C (en) * 2004-10-18 2011-05-31 Amgen Inc. 1,3,4-thiadiazole compounds as protein kinase inhibitors
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
AU2006219231B2 (en) * 2005-02-28 2010-01-14 Japan Tobacco Inc. Novel aminopyridine compound with Syk inhibitory activity
RU2447060C2 (ru) * 2005-06-17 2012-04-10 Эпоуджи Биотекнолоджи Корпорейшн Ингибиторы сфингозинкиназы
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
EP1970377A4 (en) 2005-12-09 2013-02-27 Meiji Seika Kaisha LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THIS AS AN ACTIVE SUBSTANCE
CA2633569A1 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(5-membered heteroaromatic ring)-amido anti-viral compounds
NZ569814A (en) 2006-01-18 2011-10-28 Schering Corp Cannibinoid receptor modulators
MY149143A (en) 2006-01-18 2013-07-15 Amgen Inc Thiazole compounds as protien kinase b (pkb) inhibitors
EP1979338A1 (en) 2006-01-18 2008-10-15 F.Hoffmann-La Roche Ag Cis-4, 5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors
US20080242694A1 (en) 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
US7514566B2 (en) 2009-04-07
KR20080091369A (ko) 2008-10-10
BRPI0706621A2 (pt) 2011-04-05
NO20083572L (no) 2008-10-17
IL192751A0 (en) 2009-02-11
US20070173506A1 (en) 2007-07-26
CN101421265A (zh) 2009-04-29
EA200801716A1 (ru) 2009-04-28
UA91895C2 (en) 2010-09-10
AU2007207743B2 (en) 2010-07-08
WO2007084391A2 (en) 2007-07-26
JP5199885B2 (ja) 2013-05-15
TW200738657A (en) 2007-10-16
AR059064A1 (es) 2008-03-12
US20090270445A1 (en) 2009-10-29
AU2007207743A1 (en) 2007-07-26
US8084479B2 (en) 2011-12-27
CA2636077A1 (en) 2007-07-26
UY30098A1 (es) 2007-10-31
MY149143A (en) 2013-07-15
JP2009525960A (ja) 2009-07-16
PE20071114A1 (es) 2008-01-10
ES2389062T3 (es) 2012-10-22
CR10211A (es) 2008-10-03
WO2007084391A3 (en) 2008-03-20
EP1981884A2 (en) 2008-10-22
CA2636077C (en) 2012-01-03
EP1981884B1 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
ZA200806386B (en) Thiazole compounds as protein kinase B (PKB) Inhibitors
HUS1500049I1 (hu) Protein kináz inhibitor vegyületek és készítmények
HRP20141260T1 (en) Compounds and compositions as protein kinase inhibitors
IL197724A0 (en) Compounds and compositions as protein kinase inhibitors
IL198315A0 (en) Compounds and compositions as protein kinase inhibitors
EP2200436A4 (en) SUBSTITUTED PYRIMIDINYLAMINE AS PROTEIN KINASENHEMMER
IL206416A0 (en) Benzofuropyrimidinones as protein kinase inhibitors
SI2193133T1 (sl) Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze
HK1114380A1 (en) Pyrrolopyrazoles as kinase inhibitors
PL1891066T3 (pl) Związki i kompozycje jako inhibitory kinazy białkowej
EP1841431A4 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
IL196554A0 (en) Heteroaryl derivatives as protein kinase inhibitors
HK1133641A1 (zh) 激酶抑製劑化合物
ZA200701281B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
SI1910348T1 (sl) Spojine benzotiazola in azabenzotiazola, uporabne kot kinazni inhibitorji
IL198487A0 (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
IL198398A0 (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
ZA200709269B (en) Protein kinase inhibitors
EP2336123A4 (en) HETEROCYCLIC COMPOUND AS INHIBITOR OF PROTEIN KINASE
IL194491A0 (en) Thiazolyldihydroindazole derivatives as protein kinase inhibitors
ZA200810573B (en) Substituted 3-cyanopyridines as protein kinase inhibitors
IL197981A0 (en) Kinase inhibitors
GB0621720D0 (en) Inhibitors of ikk- serine-threonine protein kinase
GB0621719D0 (en) Ikk- serine-threonine protein kinase inhibitors
EP1940411A4 (en) MACROHETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS